Skip to main content

Table 3 Gene expession associated with patient outcomes

From: A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

  Control set P-value* Bev qPCR Set P-value*
ORR     
ALDH6A1 + TFF2 + MCM5     
 All low 4/11 (36.4%) 0.747 6/7 (85.7%) 0.007
 Other 27/61 (44.3%)   12/42 (28.6%)  
Odds ratio for response     
ALDH6A1 + TFF2 + MCM5     
 All low vs. any other 0.72 0.6273 15.00 0.0168
Hazard ratio for progression     
KLF12 + TFF2     
 Other vs. (KLF12 high + TFF2 low) 1.29 0.39 2.92 0.03
ALDH6A1 + TFF2     
 Other vs. All low 1.76 0.0404 0.89 0.7406
  1. *Critical point for the significance of p-values is a = 0.05/(N of comparisons) = 0.05/27 = 0.001852 (Bonferroni correction).